Replies to post #107392 on Amarantus Bioscience Holdings Inc (AMBS)

[thealias2002]

Gerald has already said things are on track.

Jason N pointed out that the posted results were from Lympro's software version 1, not the latest, version 2.

There is no reason for doom and gloom, IMHO. No one who was a confident long before 7/31/14 should feel any less confident, now.

There is nothing that supports a change either way.

[guardiangel]

Gr8 Post and Gr8 Analysis Solantey.. I know one fact..William Gartner has gr8 contacts with QuestDx in Phoenix area..But not sure of collaboration with LP with Sonora Quest Labs before AMBS came into the picture in 2012,,,....imo Wolf ... a William Gartner fan you understand..ahooooooooooooooooooooooooooooooo

http://www.sonoraquest.com/?AspxAutoDetectCookieSupport=1

Sonora Quest Laboratories - Diagnostic Lab Tests | Arizona .

*****************************************************************

http://www.reuters.com/article/2008/03/03/idUS176542+03-Mar-2008+BW20080303

Sonora Quest Laboratories to Provide Phlebotomy Services
PHOENIX--(Business Wire)--
Provista Life Sciences LLC and Sonora Quest Laboratories announced
today a collaborative effort that will allow doctors and patients
seeking to obtain Provista Life Science's BT Test(TM) for breast
cancer access to several strategically located Sonora Quest
Laboratories phlebotomy service facilities throughout Arizona.

Provista Life Sciences, a Phoenix-based diagnostic development and
commercialization company, recently announced the availability of its
Biomarker Translation Test (BT Test), a blood test specifically
designed to assist physicians and other healthcare providers in making
an earlier and more accurate diagnosis of breast cancer when used in
conjunction with mammography.

"We are thoroughly impressed with the management and staff at
Sonora Quest Laboratories and their willingness to assist and support
our efforts to make our BT Test more readily accessible to the
public," says William J. Gartner, CEO and President of Provista Life
Sciences. "Until now, doctors prescribing the test and patients
wishing to take the BT Test were limited to our central Phoenix
laboratory, Provista Diagnostics, for their blood draws. With Sonora
Quest's support, we can now make the BT Test more readily accessible
to women across all of Arizona."

Patients wanting the BT Test will need to obtain a prescription
from their provider. With a prescription in hand, patients will be
directed to Provista Diagnostics' Web site (www.ProvistaDx.com) for
instruction on how to complete the ordering process, pay for the test
and download a blood Draw Authorization Form. The Draw Authorization
Form will direct the patients to an approved Sonora Quest Laboratories
or Provista Diagnostics blood draw center. Patients who prefer not to
go online, or who do not have Internet access, can go directly to
Provista Diagnostics' laboratory to complete this process and have
their blood drawn.

"We are extremely pleased to assist Provista Life Sciences in
their efforts to make the BT Test more accessible to the women in
Arizona," stated Joyce Santis, Chief Operating Officer for Sonora
Quest Laboratories. "We recognize the importance of making public
access as easy as possible in this regard, and we are glad we can play
a role in making that happen."

About Sonora Quest Laboratories

Sonora Quest Laboratories is an integrated laboratory system
servicing over 6,000 clients throughout Arizona, including hospitals,
physicians, managed care organizations and employers. They have more
than 2,000 employees statewide, and perform over 60,000 diagnostic
tests per day. For more information, please visit www.sonoraquest.com
or call 602-685-5285.

Provista Life Sciences' Background

Provista Life Sciences was established in 2006 as a biotechnology
development and commercialization organization that provides the
scientific and operating management resources to rapidly advance the
development and introduction of novel diagnostics technologies into
the domestic and global marketplace.

******************************************************************

Solantey Member Level Saturday, 08/09/14 01:28:13 PM
Re: None
Post # of 107398
Think Positive

Gerald stated that the LymPro partnership and the up-listing are still "on track" and that nothing has changed.

What if the partner for LymPro is a company such as Johnson & Johnson or Quest Diagnostics who is asking for an ownership position and a seat or two on the board of directors. Suppose they purchase 50,000,000 shares at .50 share as the basis for an "up-front cash payment" of $25,000,000.

Obviously the numbers could be different but this scenario makes perfect sense.

In regards to increasing the share count to have additional shares available one approach is "it's better to have them and not need them than to need them and not have them". To a small cap company such as $AMBS additional shares are similar to having a line of credit.

Monday will be interesting. Let's see what Gerald has to say.

Nothing more to say until after I read Gerald's blog.

Have a great weekend!!!

Twitter: @AmarantusBio .... 10,000+ followers.